Adjuvant zoledronic acid to treat breast cancer: not for all

Affiliations

¹ Oncology Division, Hospital de Santa Maria, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-035 Lisbon, Portugal. Electronic address: luiscosta.oncology@gmail.com.
² Oncology Division, Hospital de Santa Maria, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-035 Lisbon, Portugal.

Comment

Luís Costa et al. Lancet Oncol. 2017 Nov.

. 2017 Nov;18(11):1437-1439.

doi: 10.1016/S1470-2045(17)30695-2. Epub 2017 Oct 13.

¹ Oncology Division, Hospital de Santa Maria, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-035 Lisbon, Portugal. Electronic address: luiscosta.oncology@gmail.com.
² Oncology Division, Hospital de Santa Maria, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-035 Lisbon, Portugal.

No abstract available

Comment on

Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.
Coleman R, Hall A, Albanell J, Hanby A, Bell R, Cameron D, Dodwell D, Marshall H, Jean-Mairet J, Tercero JC, Rojo F, Gregory W, Gomis RR. Coleman R, et al. Lancet Oncol. 2017 Nov;18(11):1543-1552. doi: 10.1016/S1470-2045(17)30603-4. Epub 2017 Oct 13. Lancet Oncol. 2017. PMID: 29037984 Clinical Trial.